Olema Pharmaceuticals, Inc. Stock Price, News & Analysis

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced on January 4, 2023, the granting of stock options to three new employees, totaling 54,400 shares. This decision, approved by the Compensation Committee, was effective January 3, 2023, as part of the 2022 Inducement Plan. The stock options will vest over four years, with 25% vesting after one year and the remainder in monthly installments. The options have a 10-year term with an exercise price of $2.64 per share, matching the last reported sale price on the grant date.

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that CEO Sean Bohen will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 2:15 p.m. PT. The presentation will be available via a live webcast on Olema's Investor Relations website and archived for at least 30 days. Olema focuses on targeted therapies for women's cancers, with its lead candidate, OP-1250, currently in Phase 2 trials and granted FDA Fast Track designation. The company is headquartered in San Francisco.

Olema Pharmaceuticals announced favorable results from a Phase 1b study of OP-1250, a complete estrogen receptor antagonist, in combination with palbociclib for treating ER+/HER2- breast cancer. The study, presented at the 2022 San Antonio Breast Cancer Symposium, included 12 patients and demonstrated that the combination is well-tolerated with no dose-limiting toxicities or drug-drug interactions. OP-1250 exhibited a favorable pharmacokinetic profile, and a Phase 2 dose expansion is underway, with additional data expected in 2023.

Olema Pharmaceuticals (Nasdaq: OLMA) announced the grant of stock options totaling 62,800 shares to two new employees, effective December 1, 2022. These options are part of the Company's 2022 Inducement Plan and were approved by the Board's Compensation Committee. The options will vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments. The exercise price is set at $2.85 per share, reflecting the stock's last reported price on the grant date. Olema is focused on therapies for women’s cancers, particularly its lead candidate OP-1250.

Olema Pharmaceuticals reported promising preliminary results for its OP-1250 Phase 1/2 study, showing favorable tolerability and significant anti-tumor activity. Results from 68 patients indicated a well-tolerated drug with an exposure rate 20 times that of fulvestrant, and 41% of patients experienced tumor reductions. The company maintains a strong financial position with $222.6 million in cash as of September 30, 2022, expected to fund operations through late 2024. However, the net loss increased to $22.7 million, primarily due to R&D investments in OP-1250.

Olema Pharmaceuticals (Nasdaq: OLMA) announced the granting of stock options to two new employees totaling 40,400 shares, effective November 1, 2022. This decision was approved by the Compensation Committee under the 2022 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, with an exercise price of $3.72 per share. Olema focuses on developing targeted therapies for women’s cancers, notably its lead candidate OP-1250, which has received FDA Fast Track designation and is currently in Phase 2 trials.

Olema Pharmaceuticals (Nasdaq: OLMA) announces its participation in several investor conferences this November. Key events include a presentation at the Credit Suisse 31st Annual Healthcare Conference on November 9 at 9:10 AM PT, a fireside chat at the Jefferies London Healthcare Conference on November 16 at 11:30 AM GMT, and a virtual fireside chat at the Evercore ISI HealthCONx Conference on November 29 at 2:40 PM ET. Live webcasts and materials will be accessible on Olema's website for at least 30 days.

Olema focuses on developing targeted therapies for women’s cancers, highlighted by its lead product candidate, OP-1250.

Olema Pharmaceuticals (Nasdaq: OLMA) announced preliminary Phase 1/2 clinical results for OP-1250, a treatment for metastatic breast cancer, showcased at the 34th EORTC-NCI-AACR Symposium. The study involved 68 patients, revealing OP-1250's favorable tolerability, with drug exposure 20 times higher than fulvestrant at the effective dose. Strong anti-tumor activity was noted, with 41% of patients showing tumor reduction. The company plans to initiate a pivotal Phase 3 study mid-2023, aiming to advance OP-1250 as a leading endocrine therapy for ER+ breast cancer.

Olema Pharmaceuticals (Nasdaq: OLMA) announced the presentation of updated clinical results from the OP-1250-001 study at the 34th EORTC-NCI-AACR Symposium in Barcelona, occurring October 26-28, 2022. The study focuses on OP-1250, an oral compound for advanced ER-positive, HER2-negative breast cancer, with preliminary Phase 1/2 results to be showcased. A dedicated investor webcast is scheduled for October 26, 2022, at 8:00 a.m. ET, led by Dr. Erika Hamilton and Olema's management.